Literature DB >> 15998901

Neoadjuvant endocrine therapy for breast cancer: more questions than answers.

Matthew J Ellis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15998901     DOI： 10.1200/JCO.2005.92.003

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Optimizing the use of neoadjuvant endocrine therapy.

Authors:  Laila S Agrawal; Ingrid A Mayer
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

2.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Authors:  Matthew J Ellis; Vera J Suman; Jeremy Hoog; Li Lin; Jacqueline Snider; Aleix Prat; Joel S Parker; Jingqin Luo; Katherine DeSchryver; D Craig Allred; Laura J Esserman; Gary W Unzeitig; Julie Margenthaler; Gildy V Babiera; P Kelly Marcom; Joseph M Guenther; Mark A Watson; Marilyn Leitch; Kelly Hunt; John A Olson
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

3.  FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.

Authors:  Peter A Fasching; Sebastian M Jud; Maik Hauschild; Sherko Kümmel; Martin Schütte; Matthias Warm; Volker Hanf; Dieter Grab; Jutta Krocker; Elmar Stickeler; Rolf Kreienberg; Thomas Müller; Thorsten Kühn; Christopher Wolf; Steffen Kahlert; Stefan Paepke; Michael Berghorn; Mathias Muth; Monika Baier; Birgit Wackwitz; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux
Journal:  BMC Cancer       Date:  2014-02-05       Impact factor: 4.430

4.  Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.

Authors:  Marcelo Madeira; André Mattar; Angela Flávia Logullo; Fernando Augusto Soares; Luiz Henrique Gebrim
Journal:  BMC Cancer       Date:  2013-09-18       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.